tb-ERA and personalized embryo transfer: tb-ERA and personalized embryo transfer
Study summary
This study aims to evaluate the clinical efficacy of transcriptome-based endometrial receptivity analysis (tb-ERA) and investigate the molecular mechanisms of abnormal receptivity in young women with unexplained recurrent implantation failure (RIF).
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
35 Years
Healthy volunteers
No
* RIF Cohort - Inclusion Criteria
1. Age ≤ 35 years; BMI 18-25 kg/m².
2. ≥ 3 failed transfers of high-quality embryos.
3. No history of spontaneous or FET-related pregnancy, including biochemical pregnancy (primary infertility).
4. Written informed consent provided.
* RIF Cohort - Exclusion Criteria
1. Known factors associated with RIF, including: uterine anatomical abnormalities (malformations, adhesions, polyps, submucosal fibroids, adenomyosis) and hydrosalpinx
2. Endocrine disorders (PCOS, thyroid dysfunction, hyperprolactinemia)
3. Reproductive immunological abnormalities, thrombophilia and infectious factors, abnormal semen parameters,
4. Chromosomal abnormalities in either partner (planned PGT-SR) or monogenic disease (planned PGT-M).
5. Severe medical/surgical conditions contraindicating pregnancy.
6. Any other condition deemed unsuitable by the investigators.
* Control Group - Inclusion Criteria
1. Age ≤ 35 years; BMI 18-25 kg/m².
2. First IVF-ET cycle due to tubal factor infertility.
3. No history of biochemical pregnancy or miscarriage.
4. Written informed consent provided.
* Control Group - Exclusion Criteria 1. Same as RIF Cohort Exclusion Criteria. Additionally, participants with an abnormal ERA result will be excluded from the control group.
Primary outcome measure(s)
Ongoing pregnancy — 12 weeks after embryo transfer Ongoing pregnancy is defined as viable pregnancy beyond 12 weeks' gestation.
Trial sites (1)
Facility
City
Region
Status
Shanghai Ji Ai Genetics and IVF Institute, Obstetrics and Gynecology Hospital, Fudan University
Shanghai
Shanghai Municipality
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.